- Home
- STEC vs UNCY Comparison
STEC vs UNCY Comparison
Compare STEC & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- UNCY
- Stock Information
- Founded
- STEC 2006
- UNCY 2016
- Country
- STEC China
- UNCY United States
- Employees
- STEC N/A
- UNCY N/A
- Industry
- STEC
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- UNCY Health Care
- Exchange
- STEC NYSE
- UNCY Nasdaq
- Market Cap
- STEC 31.4M
- UNCY 31.9M
- IPO Year
- STEC 2021
- UNCY 2021
- Fundamental
- Price
- STEC $1.12
- UNCY $0.46
- Analyst Decision
- STEC
- UNCY Strong Buy
- Analyst Count
- STEC 0
- UNCY 4
- Target Price
- STEC N/A
- UNCY $5.50
- AVG Volume (30 Days)
- STEC 2.4M
- UNCY 1.9M
- Earning Date
- STEC 11-26-2024
- UNCY 11-13-2024
- Dividend Yield
- STEC N/A
- UNCY N/A
- EPS Growth
- STEC N/A
- UNCY N/A
- EPS
- STEC N/A
- UNCY N/A
- Revenue
- STEC $260,474,693.00
- UNCY N/A
- Revenue This Year
- STEC $9.76
- UNCY N/A
- Revenue Next Year
- STEC $15.85
- UNCY N/A
- P/E Ratio
- STEC N/A
- UNCY N/A
- Revenue Growth
- STEC N/A
- UNCY N/A
- 52 Week Low
- STEC $0.20
- UNCY $0.20
- 52 Week High
- STEC $7.31
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- STEC 51.23
- UNCY 48.64
- Support Level
- STEC $1.04
- UNCY $0.41
- Resistance Level
- STEC $1.24
- UNCY $0.55
- Average True Range (ATR)
- STEC 0.24
- UNCY 0.06
- MACD
- STEC -0.04
- UNCY -0.01
- Stochastic Oscillator
- STEC 27.36
- UNCY 23.47
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.